Frederic Castinetti, Mariko Nagai, Isabelle Morange, Henry Dufour, Philippe Caron, Philippe Chanson, Christine Cortet-Rudelli, Jean-Marc Kuhn, Bernard Conte-Devolx, Jean Regis and Thierry Brue
Service d’Endocrinologie, Diabète, et Maladies Métaboliques, et Centre de Reference des Maladies Rares d’Origine Hypophysaires (F.C., I.M., B.C.-D., T.B.), Hôpital de la Timone, F-13385 Marseille, France; Service de Neurochirurgie Fonctionnelle Stereotaxique (M.N., J.R.), and Service de Neurochirurgie, Hôpital de la Timone, F-13385 Marseille, France; Service d’Endocrinologie (H.D.), Maladies Métaboliques, Nutrition (P.Ca.), Centre Hospitalier Universitaire (CHU) de Toulouse, Hôpital Larrey, Pôle Cardio-Vasculaire et Métabolique, F-31059 Toulouse Cedex 9 France; Assistance Publique-Hôpitaux de Paris (P.Ch.), Service d’Endocrinologie et des Maladies de la Reproduction, Hôpital de Bicêtre, Université Paris Sud 11, Institut National de la Santé et de la Recherche Médicale (INSERM) Unité 693, F-94275 Le Kremlin-Bicêtre, France; CHU de Lille (C.C.-R.), F-59130 Lambersart, France; and Institut Fédératif de Recherches Multidisciplinaires sur les Peptides (J.-M.K.) INSERM Unité 413, Unité Associée Centre National de la Recherche Scientifique, CHU de Rouen, F-76230 Bois-Guillaume, France
Address all correspondence and requests for reprints to: Prof. T. Brue, Department of Endocrinology, Hôpital de la Timone, 264 rue St Pierre, cedex 5, 13385 Marseille, France. E-mail: email@example.com.
Context: To date, no study reported long-term follow-up results of gamma knife stereotactic radiosurgery (SR).
Objective: The aim of the study was to determine long-term efficacy and adverse effects of SR in secreting pituitary adenomas.
Design: We conducted a retrospective study of patients treated by SR in the center of Marseille, France, with a follow-up of at least 60 months.
Patients: A total of 76 patients were treated by SR for acromegaly (n = 43), Cushing’s disease (CD; n = 18), or prolactinoma (n = 15) as a primary (n = 27) or adjunctive postsurgical treatment (n = 49).
Main Outcome Measures: After withdrawal of antisecretory drugs, patients were considered in remission if they had mean GH levels below 2 ng/ml and normal IGF-I (acromegaly), normal 24-h urinary free cortisol, and cortisol less than 50 nmol/liter after low-dose dexamethasone test (CD) or two consecutive normal samplings of prolactin levels (prolactinoma).
Results: After a mean follow-up of 96 months, 44.7% of the patients were in remission. Mean time to remission was 42.6 months. Twelve patients presented late remission at least 48 months after SR. Two patients with CD presented late recurrence 72 and 96 months after SR. Forty percent of patients treated primarily with SR were in remission. Target volume and initial hormone levels were significant predictive factors of remission in univariate analysis. Radiation-induced hypopituitarism was observed in 23% patients; in half of them, hypopituitarism was observed after a mean time of 48 to 96 months. Twenty-four patients were followed for more than 120 months; rates of remission and hypopituitarism were similar to the whole cohort.
Conclusions: SR is an effective and safe primary or adjunctive treatment in selected patients with secreting pituitary adenomas.